-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A research team led by Massachusetts General Hospital recently reported that a new CRISPR-Cas9 variant can cut
In general, wild-type CRISPR-Cas9 or Cas12 enzymes need to recognize the PAM sequence before they can bind
Benjamin Kleinstiver, a research assistant at Massachusetts General Hospital, said: "For in vitro applications, this means that researchers don't have enough flexibility to cut DNA at arbitrary sites because the tools we use are being limited by these short sequence motifs
So researchers at Massachusetts General Hospital devised a variant in 2020 that was nearly unrestricted by PAM and named it SpRY
During the analysis, the researchers first compared the ability of wild-type SpCas9 and variant SpRY to
After that, they compared the activity of the wild-type SpCas9 with the variants SpRY and SpG, which is also a variant that identifies a specific PAM sequence
SpRYgest can be used in a range of applications
To make SpRYgest more widely available, the researchers also made improvements
Kleinstiver notes that these optimizations make SpRYgest easier to implement
Source text search
Christie, K.
